Skip to main content

Table 2 Studies on actual clinical practice using entecavir or tenofovir where HBV genotype and virological response information is available

From: Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice

  No. of patients Drug Race Genotype HBeAg-negative, % Months of follow-up (Median) Undetectable DNA, % ALT normal, % AgHBe loss %
Lampertico 2011 418 Entecavir D (90%) 83 60 100 (HBeAg+)
99 (HBeAg-)
90 (36 months) 55
Ono 2012 474 Entecavir A (2.5%)
B (14.1%)
C (70.9%)
53 28 88 (12 months)
96 (48 months)
83 (12 months)
93 (48 months)
16 (12 months)
38 (48 months)
Zoutendijk 2013 372 Entecavir 48% White
27% Asian
25% Others
A (9.4%)
B (6.7%) C (10%)
D (36%)
58 20 68 (12 months)
93 (36 months)
78 (Total at the end of treatment)) 17
Kim 2015 151 Tenofovir 100% Asian C (100%) 39.1 13 64.2 (12 months) 97.7 (12 months) 12 (6 months)
15.2 (12 months)
Lovett 2017 92 (55 naive) Tenofovir 83.7% Asian
7.6% White
4.3% African
4.4% Others
A (3.3%)
B (7.6%)
C (14.1%)
D (3.3%)
65.5 24 59.2 (12 months)
89.3 (36 months)
86% (Total at the end of treatment) 16.7 (36 months)